Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Eupraxia Pharmaceuticals Inc (EPRX)

Eupraxia Pharmaceuticals Inc (EPRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 79,118
  • Shares Outstanding, K 27,282
  • Annual Sales, $ 0 K
  • Annual Income, $ -28,220 K
  • EBIT $ -32 M
  • EBITDA $ -31 M
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 9.91

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.14
  • Number of Estimates 1
  • High Estimate -0.14
  • Low Estimate -0.14
  • Prior Year -0.17
  • Growth Rate Est. (year over year) +17.65%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.23 +29.92%
on 10/15/24
3.79 -23.48%
on 11/01/24
+0.54 (+22.88%)
since 10/14/24
3-Month
2.20 +31.82%
on 10/14/24
3.79 -23.48%
on 11/01/24
+0.29 (+11.11%)
since 08/14/24
52-Week
2.20 +31.82%
on 10/14/24
5.58 -48.03%
on 02/16/24
-1.06 (-26.73%)
since 10/27/23

Most Recent Stories

More News
Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting

/CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its...

EPRX : 2.90 (+2.11%)
EPRX.TO : 4.25 (+8.97%)
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024

/CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its...

EPRX : 2.90 (+2.11%)
EPRX.TO : 4.25 (+8.97%)
Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

One of three patients in Cohort 5 achieved complete histological remission at 12 weeks. Consistent improvement in patient-reported outcomes with six of six...

EPRX : 2.90 (+2.11%)
EPRX.TO : 4.25 (+8.97%)
Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results

/CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ: EPRX) (TSX: EPRX), a clinical-stage biotechnology company leveraging its...

EPRX : 2.90 (+2.11%)
EPRX.TO : 4.25 (+8.97%)
Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million

/CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its...

EPRX : 2.90 (+2.11%)
EPRX.TO : 4.25 (+8.97%)
BRE.TO : 15.30 (-2.11%)
Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024

/CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its...

EPRX : 2.90 (+2.11%)
EPRX.TO : 4.25 (+8.97%)
Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis

Publication of Eupraxia's Phase 2b data in Lancet Rheumatology, a distinguished and respected journal, raises the profile of EP-104IAR. As outlined in Lancet...

EPRX : 2.90 (+2.11%)
EPRX.TO : 4.25 (+8.97%)
Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024

/CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its...

EPRX : 2.90 (+2.11%)
EPRX.TO : 4.25 (+8.97%)
Eupraxia Pharmaceuticals Strengthens Senior Management Team

/CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its...

EPRX : 2.90 (+2.11%)
EPRX.TO : 4.25 (+8.97%)
Eupraxia Pharmaceuticals to Present at 20th ISDE World Congress for Esophageal Diseases

/CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its...

EPRX : 2.90 (+2.11%)
EPRX.TO : 4.25 (+8.97%)

Business Summary

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment...

See More

Key Turning Points

3rd Resistance Point 3.30
2nd Resistance Point 3.22
1st Resistance Point 3.06
Last Price 2.90
1st Support Level 2.82
2nd Support Level 2.74
3rd Support Level 2.58

See More

52-Week High 5.58
Fibonacci 61.8% 4.29
Fibonacci 50% 3.89
Fibonacci 38.2% 3.49
Last Price 2.90
52-Week Low 2.20

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar